Poster presented at EASL 2025 -Non-invasive tests (NITs) to predict liver biopsy outcomes in response to treatment with survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist: exploratory analysis of a phase 2 trial in people with metabolic dysfunction associated steatohepatitis and fibrosis

Noureddin, Mazen; Schoelch, Corinna; Bugianesi, Elisabetta; Alkhouri, Naim; Fraessdorf, Mandy; Sirotkin, Pavel; Schattenberg, Joern; Newsome, Philip; M. Anstee, Quentin; Neff, Guy; Coxson, Harvey; Lawitz, Eric; Ratziu, Vlad; Nakajima, Atsushi; Hosseini-Tabatabaei, Azadeh; Sanyal, Arun J.; Younes, Ramy

doi:10.60915/Boehringer-figshare.29070455.v1

Poster presented at EASL 2025 -Non-invasive tests (NITs) to predict liver biopsy outcomes in response to treatment with survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist: exploratory analysis of a phase 2 trial in people with metabolic dysfunction associated steatohepatitis and fibrosis

poster

posted on 2025-05-15, 14:06 authored by Mazen Noureddin, Corinna Schoelch, Elisabetta Bugianesi, Naim Alkhouri, Mandy Fraessdorf, Pavel Sirotkin, Joern Schattenberg, Philip Newsome, Quentin M. Anstee, Guy Neff, Harvey Coxson, Eric Lawitz, Vlad Ratziu, Atsushi Nakajima, Azadeh Hosseini-Tabatabaei, Arun J. Sanyal, Ramy Younes

This poster was presented at EASL 2025